文章摘要
刘永军,刘吉祥,高 翔,申 仑,刘 辉,张 鹏,李建华,吴建梁.阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血的临床疗效及对血清S-100B、Ang水平的影响[J].,2019,19(6):1148-1151
阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血的临床疗效及对血清S-100B、Ang水平的影响
Curative Efficacy of Atorvastatin Combined with Nimodipinein in the Treatment of Subarachnoid Hemorrhage and Its Effects on the Serum s-100b and Ang Levels
投稿时间:2018-07-25  修订日期:2018-08-20
DOI:10.13241/j.cnki.pmb.2019.06.032
中文关键词: 阿托伐他汀  尼莫地平  蛛网膜下腔出血  S-100B  人血管生成素
英文关键词: Atorvastatin  Nimodipine  Subarachnoid hemorrhage  S-100B  Human angiopoietin
基金项目:河北省自然科学基金项目(H2012401071)
作者单位E-mail
刘永军 邯郸市第一医院 神经外科 河北 邯郸 056002 qianxiaojun8611@163.com 
刘吉祥 邯郸市第一医院 神经外科 河北 邯郸 056002  
高 翔 邯郸市第一医院 神经外科 河北 邯郸 056002  
申 仑 邯郸市第一医院 神经外科 河北 邯郸 056002  
刘 辉 邯郸市第一医院 神经外科 河北 邯郸 056002  
张 鹏 邯郸市第一医院 神经外科 河北 邯郸 056002  
李建华 邯郸市第一医院 神经外科 河北 邯郸 056002  
吴建梁 河北医科大学附属第二医院 神经外科 河北 石家庄 050017  
摘要点击次数: 699
全文下载次数: 509
中文摘要:
      摘要 目的:探讨阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血的临床疗效及对患者血清蛋白(S-100B)、血管生成素(Ang)水平的影响。方法:选择2015年1月至2016年1月我院收治的蛛网膜下腔出血患者90例,采用随机数表法分为观察组(n=45)和对照组(n=45)。观察组采用阿托伐他汀联合尼莫地平进行治疗,对照组采用尼莫地平治疗。比较两组患者的临床疗效及治疗前后脑动脉平均血流速度、美国国立卫生研究院卒中量表(NIHSS)、日常生活能力量表(BI)、血清S-100B、人血管生成素(ANG)水平的变化及不良反应的发生情况。结果:治疗后,观察组总有效率为93.33%,显著高于对照组(73.33%,P<0.05)。治疗后,两组患者脑动脉平均血流速度、NIHSS及BI评分均较治疗前明显改善,且观察组患者脑动脉平均血流速度、BI评分均高于对照组;NIHSS评分明显低于对照组(P<0.05);治疗后,两组血清S-100B、ANG水平较治疗前均显著降低(P<0.05),且观察组血清S-100B、ANG水平均明显低于对照组(P<0.05)。观察组并发症发生率为13.33%,明显低于对照组(46.67%,P<0.05)。结论:阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血患者的疗效及安全性均明显优于单用尼莫地平治疗治疗,可能与其有效降低血清S-100B、ANG水平有关。
英文摘要:
      ABSTRACT Objective: To study the efficacy of Atorvastatin combined with nimodipine in the treatment of Subarachnoid hemorrhage and its effects on the serum Protein (s-100b), angiopoietin (Ang) levels. Methods: 90 patients with subarachnoid hemorrhage admitted to our hospital from January 2015 to January 2016 were selected and divided into the observation group (n=45) and the control group (n=45) by the random number table method. The observation group was treated with atorvastatin combined with nimodipine, while the control group was treated with nimodipine. The clinical efficacy, changes of mean cerebral artery blood flow velocity, national institutes of health stroke scale (NIHSS), daily living ability scale (BI), serum s-100, and human angiopoietin (ANG) levels and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of observation group was 93.33%, which was significantly higher than that of the control group (73.33%, P<0.05). After treatment, the mean cerebral artery blood flow velocity, NIHSS and BI scores of patients in both groups were significantly improved compared with those before treatment, and the mean cerebral artery blood flow velocity and BI scores of patients in the observation group were higher than those in the control group. The NIHSS score was significantly lower than that of the control group (P<0.05). After treatment, the serum s-100 and ANG levels in both groups were significantly lower than those before treatment (P<0.05), and serum s-100 and ANG levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of complications in the observation group was 13.33%, which was significantly lower than that in the control group (46.67%, P<0.05). Conclusion: The efficacy and safety of atorvastatin combined with nimodipine in the treatment of patients with subarachnoid hemorrhage are significantly better than that of nimodipine alone, which may be related to its effective reduction of serum s-100 and ANG levels.
查看全文   查看/发表评论  下载PDF阅读器
关闭